- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04123301
Theta-Burst Stimulation in Major Depressive Episodes With Mixed Characteristics.
October 9, 2019 updated by: Ricardo Alberto Moreno, M.D., Ph.D., University of Sao Paulo
Theta-Burst Stimulation (TBS) in Major Depressive Episodes With Mixed Characteristics in Bipolar and Major Depressive Disorder: a Randomized, Controlled, Double-blind, Parallel-group Clinical Trial of Efficacy, Safety, and Tolerability.
The investigators will perform a double-blind, randomized, sham-controlled clinical trial of theta-burst stimulation (TBS) in mixed depressive episodes of both bipolar and major depressive disorders.
Will be selected 90 patients aged 18-65 years with diagnosis of TB (I or II) or MDD in moderate or severe major depressive episode with mixed features.
The primary endpoint of efficacy will be a continuous outcome of change in Montgomery-Asberg Depression Rating Scale (MADRS) from baseline to week 3.
Study Overview
Status
Unknown
Intervention / Treatment
Detailed Description
INTRODUCTION: Mixed-specifier mood disorders are probably a different subgroup in terms of response to treatment, socio-demographic parameters, course and family history.
The investigators will perform a clinical trial of theta-burst stimulation (TBS) in mixed depressive episodes of both bipolar (I and II) and major depressive disorders.
METHODS: The study is designed as a randomized, sham-controlled, double-blinded clinical trial evaluating TBS for the treatment of moderate or severe major depressive episodes with mixed features of patients receiving at least one first or second line pharmacological treatment for depressive episodes without adequate response.
Ninety adult (18 to 65 yo) patients will be enrolled and submitted to 6-week (comprising 5 consecutive days a week sessions for the first 3 weeks and then 2 days a week for a further 3 week) of inhibitory followed by excitatory TBS in dorsolateral prefrontal cortex.
Participants will be assessed using clinical and neuropsychological tests before and after the intervention.
The primary outcome is change in Montgomery-Asberg Depression Scale (MADRS) score over time and across groups.
Cognitive parameters will also be assessed with neuropsychological tests.
Study Type
Interventional
Enrollment (Anticipated)
90
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Diego Tavares, MD
- Phone Number: +5511941854053
- Email: diego.tavares@hc.fm.usp.br
Study Contact Backup
- Name: Carla Garcia, MD
- Phone Number: +5511982732856
- Email: dracarlagarcia@gmail.com
Study Locations
-
-
-
Sao Paulo, Brazil, 05403-010
- Recruiting
- Institute of Psychiatry, University of Sao Paulo
-
Contact:
- Ricardo A. Moreno, MD, PhD
- Phone Number: +55 (11) 2661-6648
- Email: ricardoalbertomoreno@gmail.com
-
Contact:
- Frederico N. Demetrio, MD, PhD
- Phone Number: +55 (11) 2661-6648
- Email: frdemetr@uol.com.br
-
Sub-Investigator:
- Diego F. Tavares, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Current mixed depression in any mood disorder (bipolar I, bipolar II or major depressive disorder) assessed with Montgomery-Asberg Depression Rating Scale (MADRS) score ≥ 20 points AND Young Mania Rating Scale (YMRS) score ≥ 1 point in 3 or more items.
- Any appropriate first or second line pharmacological regimen in accordance with CANMAT guidelines to treat a major depressive episode in major depressive disorder (Agomelatina 25-50 mg/dia; Bupropiona 150-300 mg/dia; Citalopram 20-40 mg/dia; Desvenlafaxina 50 - 100 mg/dia; Duloxetina 60 - 120mg/dia; Escitalopram 10 - 20 mg/dia; Fluoxetina 20 - 60 mg/dia; Fluvoxamina 100 - 300 mg/dia; Mirtazapina 15 - 45 mg/dia; Paroxetina 20 - 60 mg/dia; Sertralina 50 - 200 mg/dia; Venlafaxina 75 - 225 mg/dia; Vortioxetina 10 - 20 mg/dia; Amitriptilina 150 - 300 mg/dia; Imipramina 150 - 300 mg/dia; Clomipramina 150 - 200 mg/dia; Nortriptilina 75 - 150 mg/dia; Trazodona 150 - 300 mg/dia; Quetiapina 150 - 300mg/dia), bipolar I (Quetiapina 300 - 600 mg/dia; Lítio litemia 0,6 - 1,2 mEq/L; Lamotrigina 100 - 200 mg/dia; Lurasidona 40 - 80 mg/dia; Lítio/Divalproato + Lurasidona; Lítio/Divalproato + Lamotrigina; Olanzapina 5 - 20 mg/dia + Fluoxetina 20 - 60 mg/dia; Divalproato de sódio; Lítio/Divalproato + ISRS/Bupropiona) or bipolar II disorder (Quetiapina 300 - 600 mg/dia; Lítio; Lamotrigina; Bupropiona; Sertralina; Venlafaxina).
Exclusion Criteria:
- Concomitant diagnosis of other neuropsychiatric disorders such as: schizophrenia, dementias, mental retardation, organic mental disorder, or epilepsy;
- Acute suicide ideation (assessed by interview and clinical evaluation);
- Suspected or confirmed pregnancy;
- Women in breastfeeding;
- Severe or unstable clinical disease;
- Specific contraindications to TBS: previous epileptic seizures; change in electroencephalogram at some point in life; previous stroke; previous severe TBI (with neurosurgery); metallic object on head (except mouth) as projectile piece, surgical clip, welding fragments; any implanted device (cardiac pacemaker, intravenous catheter).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active TBS Arm
Patients randomized to this arm will receive active TBS 5 consecutive days of the week (Monday to Friday) in the first 3 weeks and then 2 alternate days of the week (with interval of at least 1 day between sessions) for another 3 weeks.
|
Each session will be comprised of ACTIVE TBS: first, continuous inhibitory stimulation (cTBS) in the right dorsolateral prefrontal cortex followed by intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex.
|
Sham Comparator: Sham TBS Arm
Patients randomized to this arm will receive sham TBS 5 consecutive days of the week (Monday to Friday) in the first 3 weeks and then 2 alternate days of the week (with interval of at least 1 day between sessions) for another 3 weeks.
|
The sham-TBS sessions will be performed using an identical coil that produces SHAM Stimulation: first, sham continuous inhibitory stimulation (cTBS) in the right dorsolateral prefrontal cortex followed by sham intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Montgomery-Asberg Depression Rating Scale (MADRS) at week 3.
Time Frame: From baseline until week 3.
|
Change in Montgomery-Asberg Depression Rating Scale (MADRS) in each patient in both interventional groups.
The outcome will be assessed by a continuous change using a mixed models statistic.
The scale range is: 0 to 6 - normal/symptom absent; 7 to 19 - mild depression; 20 to 34 - moderate depression; 35 - 60 - severe depression.
Reduction is a better and increase is a worse outcome.
|
From baseline until week 3.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Montgomery-Asberg Depression Rating Scale (MADRS) at week 6.
Time Frame: From baseline until week 6.
|
Change in Montgomery-Asberg Depression Rating Scale (MADRS) in each patient in both interventional groups.
The outcome will be assessed by a continuous change using a mixed models statistic.
The scale range is: 0 to 6 - normal/symptom absent; 7 to 19 - mild depression; 20 to 34 - moderate depression; 35 - 60 - severe depression.
Reduction is a better and increase is a worse outcome.
|
From baseline until week 6.
|
Change in Young Mania Rating Scale (YMRS) at week 3.
Time Frame: From baseline until week 3.
|
Change in Young Mania Rating Scale (YMRS) in each patient in both interventional groups.
The outcome will be assessed by a continuous change using a mixed models statistic.
The scale range is: 13-19 - hypomania; 20-25 - mild mania; 26-37 - moderate mania ; 38-60 - severe mania.
Reduction is a better and increase is a worse outcome.
|
From baseline until week 3.
|
Change in Young Mania Rating Scale (YMRS) at week 6.
Time Frame: From baseline until week 6.
|
Change in Young Mania Rating Scale (YMRS) in each patient in both interventional groups.
The outcome will be assessed by a continuous change using a mixed models statistic.
The scale range is: 13-19 - hypomania; 20-25 - mild mania; 26-37 - moderate mania ; 38-60 - severe mania.
Reduction is a better and increase is a worse outcome.
|
From baseline until week 6.
|
Response rate using Montgomery-Asberg Depression Rating Scale (MADRS) at week 3
Time Frame: From baseline until week 3.
|
Reduction of 50% or more of the Montgomery-Asberg Depression Rating Scale (MADRS) in each patient in both interventional groups.
The scale range is: 0 to 6 - normal/symptom absent; 7 to 19 - mild depression; 20 to 34 - moderate depression; 35 - 60 - severe depression.
Reduction is a better and increase is a worse outcome.
|
From baseline until week 3.
|
Response rate using Montgomery-Asberg Depression Rating Scale (MADRS) at week 6.
Time Frame: From baseline until week 6.
|
Reduction of 50% or more of the Montgomery-Asberg Depression Rating Scale (MADRS) in each patient in both interventional groups.
The scale range is: 0 to 6 - normal/symptom absent; 7 to 19 - mild depression; 20 to 34 - moderate depression; 35 - 60 - severe depression.
Reduction is a better and increase is a worse outcome.
|
From baseline until week 6.
|
Remission rate using Montgomery-Asberg Depression Rating Scale (MADRS) at week 3
Time Frame: From baseline until week 3.
|
Montgomery-Asberg Depression Rating Scale (MADRS) < 11 points in each patient in both interventional groups.
The scale range is: 0 to 6 - normal/symptom absent; 7 to 19 - mild depression; 20 to 34 - moderate depression; 35 - 60 - severe depression.
Reduction is a better and increase is a worse outcome.
|
From baseline until week 3.
|
Remission rate using Montgomery-Asberg Depression Rating Scale (MADRS) at week 6.
Time Frame: From baseline until week 6.
|
Montgomery-Asberg Depression Rating Scale (MADRS) < 11 points in each patient in both interventional groups.
The scale range is: 0 to 6 - normal/symptom absent; 7 to 19 - mild depression; 20 to 34 - moderate depression; 35 - 60 - severe depression.
Reduction is a better and increase is a worse outcome.
|
From baseline until week 6.
|
Change in Hamilton Anxiety Scale (HAM-A scale) at week 3.
Time Frame: From baseline until week 3.
|
Change in Hamilton Anxiety Scale (HAM-A scale) in each patient in both interventional groups.
The outcome will be assessed by a continuous change using a mixed models statistic.
The scale range is: 0-17 - mild anxiety; 18-24 moderate anxiety; 25-30 - severe anxiety.
Reduction is a better and increase is a worse outcome.
|
From baseline until week 3.
|
Change in Hamilton Anxiety Scale (HAM-A scale) at week 6.
Time Frame: From baseline until week 6.
|
Change in Hamilton Anxiety Scale (HAM-A scale) in each patient in both interventional groups.
The outcome will be assessed by a continuous change using a mixed models statistic.
The scale range is: 0-17 - mild anxiety; 18-24 moderate anxiety; 25-30 - severe anxiety.
Reduction is a better and increase is a worse outcome.
|
From baseline until week 6.
|
Change in Global Clinical Impression Scale of Severity (GCI-S) at week 3.
Time Frame: From baseline until week 3.
|
Change in Global Clinical Impression Scale of Severity (GCI-S) in each patient in both interventional groups.
The outcome will be assessed by a continuous change using a mixed models statistic.
The scale range is: 1- not sick; 2- very mild disease; 3- mild disease; 4- moderate disease; 5- intense disease; 6- severe disease; 7- extremely severe disease.
Reduction is a better and increase is a worse outcome.
|
From baseline until week 3.
|
Change in Global Clinical Impression Scale of Severity (GCI-S) at week 6.
Time Frame: From baseline until week 6.
|
Change in Global Clinical Impression Scale of Severity (GCI-S) in each patient in both interventional groups.
The outcome will be assessed by a continuous change using a mixed models statistic.
The scale range is: 1- not sick; 2- very mild disease; 3- mild disease; 4- moderate disease; 5- intense disease; 6- severe disease; 7- extremely severe disease.
Reduction is a better and increase is a worse outcome.
|
From baseline until week 6.
|
Change in the brief version of the World Health Organization Quality of Life Questionnaire (WHOQOL-brief scale) at week 3.
Time Frame: From baseline until week 3.
|
Change in the brief version of the World Health Organization Quality of Life Questionnaire (WHOQOL-brief scale) in both interventional groups.The scale range is: 26 to 130 points.
Increase is a better and reduction is a worse outcome.
|
From baseline until week 3.
|
Change in the brief version of the World Health Organization Quality of Life Questionnaire (WHOQOL-brief scale) at week 6.
Time Frame: From baseline until week 6.
|
Change in the brief version of the World Health Organization Quality of Life Questionnaire (WHOQOL-brief scale) in both interventional groups.The scale range is: 26 to 130 points.
Increase is a better and reduction is a worse outcome.
|
From baseline until week 6.
|
Change in Global Assessment of Functioning (GAF) Scale at week 3.
Time Frame: From baseline until week 3.
|
Change in Global Assessment of Functioning (GAF) Scale in both interventional groups.
The scale range is: 1 to 100 points.
Increase is a better and reduction is a worse outcome.
|
From baseline until week 3.
|
Change in Global Assessment of Functioning (GAF) Scale at week 6.
Time Frame: From baseline until week 6.
|
Change in Global Assessment of Functioning (GAF) Scale in both interventional groups.
The scale range is: 1 to 100 points.
Increase is a better and reduction is a worse outcome.
|
From baseline until week 6.
|
Change in Biological Rhythm Interview of Assessment in Neuropsychiatry (BRIAN) at week 3.
Time Frame: From baseline until week 3.
|
Change in Biological Rhythm Interview of Assessment in Neuropsychiatry (BRIAN) in both interventional groups.
The scale range is: 18 to 72 points.
Reduction is a better and increase is a worse outcome.
|
From baseline until week 3.
|
Change in Biological Rhythm Interview of Assessment in Neuropsychiatry (BRIAN) at week 6.
Time Frame: From baseline until week 6.
|
Change in Biological Rhythm Interview of Assessment in Neuropsychiatry (BRIAN) in both interventional groups.
The scale range is: 18 to 72 points.
Reduction is a better and increase is a worse outcome.
|
From baseline until week 6.
|
Change in Barratt Impulsivity Scale of 11 items (BIS-11) at week 3.
Time Frame: From baseline until week 3.
|
Change in Barratt Impulsivity Scale of 11 items (BIS-11) in both interventional groups.
The scale range is: 30 to 120 points.
Reduction is a better and increase is a worse outcome.
|
From baseline until week 3.
|
Change in Barratt Impulsivity Scale of 11 items (BIS-11) at week 6.
Time Frame: From baseline until week 6.
|
Change in Barratt Impulsivity Scale of 11 items (BIS-11) in both interventional groups.
The scale range is: 30 to 120 points.
Reduction is a better and increase is a worse outcome.
|
From baseline until week 6.
|
Frequency of adverse events in UKU-SERS Scale at week 6.
Time Frame: From baseline until week 6.
|
Frequency of adverse events in UKU-SERS Scale in both interventional groups.The scale range is: 0 to 57 points.
Reduction is a better and increase is a worse outcome.
|
From baseline until week 6.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ricardo Moreno, PHD, University of Sao Paulo
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Tavares DF, Suen P, Rodrigues Dos Santos CG, Moreno DH, Lane Valiengo LDC, Klein I, Borrione L, Marques Forte P, Brunoni AR, Alberto Moreno R. Treatment of mixed depression with theta-burst stimulation (TBS): results from a double-blind, randomized, sham-controlled clinical trial. Neuropsychopharmacology. 2021 Dec;46(13):2257-2265. doi: 10.1038/s41386-021-01080-9. Epub 2021 Jun 30.
- Tavares DF, Dos Santos CGR, Valiengo LDCL, Klein I, Borrione L, Forte PM, Brunoni AR, Moreno RA. Efficacy, Safety, and Tolerability of Theta-Burst Stimulation in Mixed Depression: Design, Rationale, and Objectives of a Randomized, Double-Blinded, Sham-Controlled Trial. Front Psychiatry. 2020 May 15;11:435. doi: 10.3389/fpsyt.2020.00435. eCollection 2020.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 8, 2019
Primary Completion (Anticipated)
March 1, 2021
Study Completion (Anticipated)
May 1, 2021
Study Registration Dates
First Submitted
October 2, 2019
First Submitted That Met QC Criteria
October 9, 2019
First Posted (Actual)
October 10, 2019
Study Record Updates
Last Update Posted (Actual)
October 10, 2019
Last Update Submitted That Met QC Criteria
October 9, 2019
Last Verified
October 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MORENO-2019
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
Samsung Medical CenterUnknownMajor Depressive Disorder, Anxiety DisorderKorea, Republic of
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedDepressive Disorder, Major Depressive DisorderUnited States
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
Clinical Trials on Active Theta Burst Stimulation (TBS)
-
University of Sao PauloActive, not recruitingBipolar Disorder, Type 1Brazil
-
University of ArizonaNational Institute on Aging (NIA)RecruitingMild Cognitive ImpairmentUnited States
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruiting
-
Chang Gung Memorial HospitalEnrolling by invitationAlzheimer Disease, Early OnsetTaiwan
-
University of Sao PauloAcademy of Medical Sciences, UKCompleted
-
King's College LondonSouth London and Maudsley NHS Foundation TrustWithdrawnBinge-Eating DisorderUnited Kingdom
-
Dr Georg KranzRecruitingDepression MinorHong Kong
-
University of California, Los AngelesNational Institute on Aging (NIA)RecruitingCognitive Dysfunction | Memory Disorders in Old AgeUnited States
-
University Hospital TuebingenCompletedMajor DepressionGermany
-
Dongtan Sacred Heart HospitalRecruitingStrokeKorea, Republic of